Skip to main content
. Author manuscript; available in PMC: 2021 Mar 8.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2020 Feb 6;23(3):465–474. doi: 10.1038/s41391-020-0208-4

Fig. 5. Alteration of androgen and estrogen levels in prostate tissue of obese vs lean BPH patients upon treatment with 5-α reductase inhibitors (5ARIs).

Fig. 5.

Prostatic androgen receptor (AR) (A), ESR2 (B) and ESR1 (C) expression at mRNA level, and estradiol (D) change in lean and obese men. Prostatic testosterone (E) and DHT (F) in 5ARIs untreated vs. treated men. (G) Prostatic testosterone in lean vs. overweight men. (H) Prostatic estradiol in 5ARIs untreated vs. treated men. (I) The ratio of androgen to estrogen (testosterone/estradiol, T/E) in 5ARIs untreated vs treated groups. (J) The prostatic T/E ratio in lean vs. overweight individuals. *P < 0.05, **P< 0.01, ***P < 0.001, ****P< 0.0001, compared with BMI<25 group or untreated group).